MITOXANTRONE - MECHANISM OF ACTION, ANTITUMOR-ACTIVITY, PHARMACOKINETICS, EFFICACY IN THE TREATMENT OF SOLID TUMORS AND LYMPHOMAS, AND TOXICITY

  • 1 November 1987
    • journal article
    • research article
    • Vol. 7  (6) , 1257-1264
Abstract
Mitoxantrone is similar to Adriblastin in its mechanism of action and antitumor activity. Objective remissions were obtained in 20 - 30% pretreated patients and in 23 - 44% of untreated patients by single-drug treatment of patients suffering from metastatic breast cancer. The objective response rates to Mitoxantrone in combination with CTX, 5-FU, MTX, VCR, MMC. Prednimustine or Vindesine were 16 - 46% in treatment and 38 - 89% in primary treatment. Randomized studies comparing Mitoxantrone with Adriblastin in single-drug and combination treatment did not show any significant differences in efficacy. However, Mitoxantrone was significantly less toxic. Remission rates of between 24 and 54% were achieved by single-drug treatment in pretreated patients suffering from non-Hodgkin lymphoma. Mitoxantrone appears to be active in ovarian cancer, lung cancer and hepatocellular carcinoma.